report result top-line growth despit maintain
previou revenu opex guidanc jakafi net sale
beat our/consensu estim pemazyr virtual launch
dermatolog buildout nda ruxolitinib ad expect pivot
trial vitiligo readout expect tafasitamab dlbcl
potenti approv pdufa includ model ruxolitinib s/r-
cgvhd pivot result ruxolitinib clinic
data expect continu focu bd well-posit
cash updat model rais pt detail insid
jakafi net sale reflect y/i growth beat our/consensu
estim volum drove growth across three indic
despit outbreak estim jakafi net sale vs
consensu guidanc midpoint rang jakafi
s/r-agvhd result posit s/r-cgvhd pivot
result expect exhibit
pemazyr virtual launch underway follow approv cca
base result leverag jakafi network
includ uc readout expect cca
data tumor-agnost set
dermatolog buildout continu follow posit true-
result see topic ruxolitinib well-posit mild/moder ad
beat topic includ eucrisa efficaci could approach level system
therapi like dupilumab upadacitinib improv side-effect profil
long-term safeti data enabl nda meanwhil pivot
result vitaligo still expect exhibit
tafasitamab dlbcl drive long-term revenu growth
pdufa file expect dlbcl larg unmet need
annual us incid refractori rate forecast peak sale
incy/mor record ex-us/u sale opex us share
potenti expans includ dlbcl nhl/cll exhibit
fight ruxolitinib rux-covid trial cytokine-
storm data trial open ard patient ventil
enabl bd remain prioriti like dermatolog oncolog
updat model rais pt prior exhibit
year price histori incyt
biopharma compani
focus small molecul oncolog
jakafi
analyst certif import disclosur see disclosur
jakafi success commerci gvhd
topic ruxolotinib approv dermatolog condit
accret invest cash rel low-risk pipelin asset
inhibitor signific potenti myelofibrosi mf
polycythemia vera pv potenti indic
clinic investig deep promis pipelin
includ capmatinib divers pipelin drive
acceler revenu growth current under-valu
view
poc data mf
file tafasitamab dlbcl
potenti fda approv tafasitamab dlbcl
result ruxolitinib sr-cgvhd
potenti fda approv capmatinib nsclc
nda file ruxolitinib cream atop dermat
initi mf
result itacitinib sn-cgvhd
higher expect sale market product
greater expect advanc pipelin asset
pipelin asset fail differenti offer strateg advantag
collabor
price target per share base dcf valuat methodolog employ wacc termin growth rate
view appropri compani commerci asset clinical-stag pipelin estim jakafi sale
could peak us includ peak royalti ex-u sale see iclusig olumi smaller contributor
revenu
key known downsid risk price target clinic develop risk regulatori risk pipelin addit risk come
build commerci infrastructur indic higher anticip competit drug develop
upsid risk includ acquisit signific premium better expect clinic data drug pipelin
exhibit actual vs oppenheim consensu estim
exhibit jakafi net sale reflect y/i growth volum drove growth across
three indic despit outbreak
exhibit jakafi s/r-agvhd result posit s/r-cgvhd pivot
result expect
exhibit pemazyr virtual launch underway follow approv cca base
result leverag jakafi network overlap among
exhibit see topic ruxolitinib well-posit mild/moder ad beat topic
includ eucrisa efficaci could approach level system therapi like dupilumab
upadacitinib improv side-effect profil
exhibit long-term safeti data enabl nda meanwhil pivot
result vitaligo still expect
exhibit dlbcl larg unmet need annual us incid refractori rate
exhibit tafasitamab dlbcl drive long-term revenu growth pdufa
file expect
exhibit forecast peak-sal incy/mor record ex-us/u sale
opex us share
exhibit potenti expans includ dlbcl nhl/cll parsaclisib
exhibit fight ruxolitinib on-going rux-covid trial
cytokine-storm data trial initi ard patient ventil
exhibit upcom pipelin catalyst remain in-tact despit
exhibit pt support dcf valuat
discount analysisoppenheim co except per-shar data revenu chang work work capit valu growth valu oppenheim co estimatesequ valu per sharetermin valu growth rate
thousand except per share
product royalti revenu olumi us eu row
probabl success
probabl success
probabl success
probabl success
probabl success
probabl success
mileston contract research
probabl success
licens royalti
cost expens
good sold royalti jakafi
good sold amortizatin iclusig right eu
good sold small mol
good sold biolog
amort acquir product right
share-bas compens cog
share-bas compens cog expens
research develop
adjust research develop non-gaap
up-front consider collabor
share-bas compens
share-bas compens expens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
share-bas compens sg expens
incom loss oper
incom expens
interest incom expens net
loss debt repurchas
unreal gain long term invest
ep basic dilut
ep non-gaap basic dilut
share use comput ep basic
share use comput ep dilut
fulli dilut share out use valuat
stock price compani mention report
